Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sezary Syndrome

被引:106
|
作者
Duvic, Madeleine [1 ]
Donato, Michele
Dabaja, Bouthaina
Richmond, Heather
Singh, Lotika
Wei, Wei
Acholonu, Sandra
Khouri, Issa
Champlin, Richard
Hosing, Chitra
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE THERAPY; LYMPHOMA; STAGE; VORINOSTAT; TRIAL; REMISSION; PROGNOSIS; RISK;
D O I
10.1200/JCO.2009.25.8301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Transformed mycosis fungoides (MF) and Sezary syndrome (SS) are currently incurable. We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL). Patients and Methods Nineteen patients with advanced CTCL (median age, 50 years; four prior therapies) underwent total skin electron beam radiation followed by allogeneic HSCT between July 2001 and July 2008. Sixteen patients were conditioned with fludarabine (125 mg/m(2)) and melphalan (140 mg/m(2)) plus thymoglobulin (for mismatched donors). Graft-versus-host disease (GVHD) prophylaxis was with tacrolimus/mini methotrexate. Results Eighteen patients experienced engraftment, and one died as a result of sepsis on day 16. Median time to recovery of absolute neutrophil count (ANC) was 12 days. Fifteen achieved full donor chimerism, 12 had acute GVHD, and 12 were treated for chronic GVHD. The overall intent-to-treat response was 68%, and the complete response rate was 58%. Four of six patients died in complete remission as a result of bacterial sepsis (n = 2), chronic GVHD and fungal infection (n = 1), or lung cancer (n = 1); only two died as a result of progressive disease. Eight experienced relapse in skin; five regained complete response with reduced immunosuppression or donor lymphocyte infusions. Eleven of 13 are currently in complete remissions, with median follow-up of 19 months (range, 1.3 to 8.3 years). Median overall survival has not been reached. Conclusion Total skin electron beam followed by allogeneic stem-cell transplantation merits additional evaluation for a selected group of patients with refractory, advanced, cutaneous T-cell lymphoma with evidence for graft-versus-tumor effect.
引用
收藏
页码:2365 / 2372
页数:8
相关论文
共 50 条
  • [1] Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and sezary syndrome
    Singh, L.
    Hosing, C.
    Duvic, M.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 : S91 - S91
  • [2] Alemtuzumab, total skin electron beam, and non-myeloablative allogeneic haematopoietic stem-cell transplantation in advanced sezary syndrome: a retrospective cohort study
    Thompson, L. L.
    Pan, C. X.
    Chang, M. S.
    Molina, G. E.
    Chen, Y. B.
    Barnes, J. A.
    Chen, S. T.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (06) : E373 - E375
  • [3] ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED MYCOSIS FUNGOIDES/SEZARY SYNDROME
    Atilla, E.
    Ataca, P.
    Bozdag, S. Civriz
    Toprak, S. K.
    Yuksel, M. Kurt
    Topcuoglu, P.
    Akay, B. N.
    Sanli, H.
    Gurman, G.
    Ozcan, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 662 - 663
  • [4] Total Skin Electron Beam radiation therapy and allogeneic haematopoietic stem cell transplantation in advanced mycosis fungoides and Sezary syndrome
    Hosing, C.
    Saliba, R.
    Singh, L.
    Popat, U.
    Qazilbash, M.
    Anderlini, P.
    Nieto, Y.
    Alousi, A.
    Frazier, E.
    Dabaja, B.
    Champlin, R.
    Duvic, M.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 : S85 - S86
  • [5] Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome
    Mori, Takehiko
    Shiratori, Souichi
    Suzumiya, Junji
    Kurokawa, Mineo
    Shindo, Motohiro
    Naoyuki, Uchida
    Katsuto, Takenaka
    Miyamoto, Toshihiro
    Morishige, Satoshi
    Hirokawa, Makoto
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    [J]. HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 266 - 271
  • [6] Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome
    Lechowicz, M. J.
    Lazarus, H. M.
    Carreras, J.
    Laport, G. G.
    Cutler, C. S.
    Wiernik, P. H.
    Hale, G. A.
    Maharaj, D.
    Gale, R. P.
    Rowlings, P. A.
    Freytes, C. O.
    Miller, A. M.
    Vose, J. M.
    Maziarz, R. T.
    Montoto, S.
    Maloney, D. G.
    Hari, P. N.
    [J]. BONE MARROW TRANSPLANTATION, 2014, 49 (11) : 1360 - 1365
  • [7] Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome
    M J Lechowicz
    H M Lazarus
    J Carreras
    G G Laport
    C S Cutler
    P H Wiernik
    G A Hale
    D Maharaj
    R P Gale
    P A Rowlings
    C O Freytes
    A M Miller
    J M Vose
    R T Maziarz
    S Montoto
    D G Maloney
    P N Hari
    [J]. Bone Marrow Transplantation, 2014, 49 : 1360 - 1365
  • [8] Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sezary syndrome: a concise review
    Johnson, William T.
    Mukherji, Reetu
    Kartan, Saritha
    Nikbakht, Neda
    Porcu, Pierluigi
    Alpdogan, Onder
    [J]. CHINESE CLINICAL ONCOLOGY, 2019, 8 (01)
  • [9] Allogeneic Stem-Cell Transplantation for advanced mycosis fungoides/Sezary syndrome: Single-center experience
    Atilla, E.
    Sahin, D.
    Ataca, P.
    Bozdag, S. Civriz
    Toprak, S. K.
    Yuksel, M. Kurt
    Topcuoglu, P.
    Akay, B. N.
    Sanli, H.
    Gurman, G.
    Ozcan, M.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : 5618 - 5619
  • [10] Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome
    Seval, Guldane Cengiz
    Sahin, Ugur
    Bozdag, Sinem Civriz
    Yuksel, Meltem Kurt
    Topcuoglu, Pervin
    Akay, Bengu Nisa
    Sanli, Hatice Erdi
    Gurman, Gunhan
    Toprak, Selami Kocak
    Ozcan, Muhit
    [J]. DERMATOLOGIC THERAPY, 2022, 35 (05)